Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Follow-up of Subjects with Cerebral Adrenoleukodystrophy Treated with Lenti-D
2024-513904-33-00Phase 3Authorised
- Sponsor
- bluebird bio
- Start
- Jul 2024
- Modality
- Cell Therapies, Gene Therapies
- Countries
- 9
01
Overview
Phase 3, open-label, single-arm trial of elivaldogene autotemcel in cerebral adrenoleukodystrophy (CALD), sponsored by bluebird bio. Primary endpoints: Major functional disability-free survival, Incidence of malignancies and 4 more. Planned start Jul 2024; status: authorised.
02
Drugs
elivaldogene autotemcel
03
Conditions
cerebral adrenoleukodystrophy (CALD)
Beyond the preview
Go deeper on 2024-513904-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513904-33-00.